Alpha Tau Medical Ltd.
DRTS
$14.54
▼
-0.61
(-4.03%)
at close
8
Visible periods
7
Metrics
Peer-ranked
Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome
Analytical Summary
Alpha Tau Medical Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
Market Cap
—
Dividend Yield
—
Revenue Growth
—
Op. Margin
—
ROIC
—
FCF / Share
—
Trailing P/E
—
Price / Book
16.6x
FCF Yield
—
Debt / Equity
—
info
Valuation on last close. End-of-day price, Sep 23, 2026.
trending_up
Bullish Indicators
- No bullish signals detected.
warning
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Returns
15
Financial Health
13
Cash Quality ↑
52
Financial view
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
Is the balance sheet risky?
2 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q4 FY2022 Dec 31, 2022 20-F ↗ | Q4 FY2021 Dec 31, 2021 20-F ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2019 20-F ↗ | Q4 FY2018 Dec 31, 2018 20-F ↗ |
|---|---|---|---|---|---|---|---|---|
| Debt to Equity (x) | — | — |
0.06x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-90%)
|
— | — | — | — | — |
| Net Debt (USD) | $-12.20M | $-13.72M | $-7.41M | $-5.84M | $-23.24M | $-15.60M | — | — |
How resilient is the balance sheet?
3 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q4 FY2022 Dec 31, 2022 20-F ↗ | Q4 FY2021 Dec 31, 2021 20-F ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2019 20-F ↗ | Q4 FY2018 Dec 31, 2018 20-F ↗ |
|---|---|---|---|---|---|---|---|---|
| Working Capital (USD) | $67.79M | $55.55M | $78.65M | $102.14M | $28.24M | $45.37M | — | — |
| LT Debt (USD) | — | — | $5.25M | — | — | — | — | — |
| Total Equity (USD) | $77.10M | $62.67M | $84.47M | $105.66M | $-34.78M | $-8.43M | $-193.00K | $1.86M |
⌨️ Keyboard Shortcuts
/ Search
Esc Clear
A Annual
Q Quarterly
1-7 Jump to category
R Reset
Secondary lens
Benchmark Lens
Compare DRTS against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare DRTS against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for DRTS
Bullish
0
No bullish signals detected
Bearish
1
Return on Common Equity (%)
-55.3%
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How DRTS compares to all companies
Return on Common Equity (%)
-55.3%
Bottom 25%
Peers: Top 65%
Peer Comparison
DRTS vs similar peers
Return on Common Equity (%)
DRTS
-55.3%
#63 of 97
IDXG
109.9%
MMM
69.1%
MDNC
50.6%
Peer median: -20.49
Profit Margin (%)
DRTS
—
#None of 62
RMD
27.2%
IRMD
26.8%
LMAT
23.1%
Peer median: -2.65
Debt to Equity
DRTS
—
#None of 56
TCMD
0.00x
UTMD
0.00x
ICCM
0.00x
Peer median: 0.45
Operating Margin (%)
DRTS
—
#None of 62
RMD
32.7%
IRMD
31.2%
LMAT
27.2%
Peer median: -0.50
Compare DRTS with peers
Stack DRTS against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced yesterday 8 years · 8 quarters